Company intelligence / Profile preview

VyraMed

Fort Lauderdale, Florida, United Statesvyramed.com ↗

Ownership: Private
Development stage: Commercial

Overview

VyraMed's MTP technology has shown effectiveness in ex vivo human skin studies against Varicella zoster virus (VZV), which causes shingles. Both MTP powder and gel formulations prevented VZV spread, even when added as late as 5 days post-infection. The technology has also demonstrated varying effectiveness against multiple virus families, with efficacy rates ranging from 43.77% to 99.99% in one minute.

Therapeutic areas: Infectious Diseases
Modalities: Antiviral agentsTopical treatments
Industry: Biotech

Drug pipeline

1 asset

MTP

Commercial

Indications: Viral infections, Burns, Trauma

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)National Institutes of Health (NIH)

Beyond the preview

Go deeper on VyraMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VyraMed.

Explore the full profile